Ten years ago, I commented in this journal about the association between estrogen metabolites and the risk for breast cancer. What I wrote was that the then current science strongly suggested a definitive lack of association between 2-hydroxyestrone to 16α-hydroxyestrone ratio and breast cancer risk. It was clear that risk could not be calculated from lab values of these metabolites and that encouraging patients to test and rely on the results was ethically questionable. I expressed these opinions rather strongly, even when opposed by several eminent practitioners.
It is always difficult to admit that you were wrong about something, but it turns out that I was wrong on this matter. That’s why I’m writing this article now.










0 Comments